Supriya Lifescience delivers 25.01% operating margin in Q1FY27
Standalone net profit was shaped by a 41.06% tax rate, while management outlined six EU dossier filings and capacity additions.
Filed 13 Aug 2026, 18:59 IST · after market close · Supriya Lifescience Ltd (SUPRIYA)
Key takeaways
- Supriya Lifescience's standalone Q1FY27 operating margin was 25.01%, 2.06 percentage points above the healthcare peer median.
- Standalone net profit was Rs 24.04 cr after a 41.06% tax rate, while other income was Rs 2.65 cr.
- Management said it plans to file six EU dossiers and add a production block at Lote in the current financial year.
Price around the results
Q1FY27 earnings were led by operating profit
Supriya Lifescience reported standalone revenue of Rs 189.75 cr and net profit of Rs 24.04 cr in Q1FY27. Operating profit was Rs 47.46 cr, with depreciation of Rs 8.94 cr and interest of Rs 0.37 cr below the operating line. Other income was Rs 2.65 cr against profit before tax of Rs 40.79 cr, so reported earnings were primarily generated from operations.
Margin stayed above the healthcare peer median
The standalone operating margin was 25.01%, which was 2.06 percentage points above the 22.95% median for the 69 healthcare peers that had reported the same quarter. Expenses were Rs 142.29 cr, while the tax rate was 41.06%; the tax charge therefore limited the conversion of pre-tax profit into net profit.
Management outlined filings, capacity and product initiatives
Management said it plans to file six dossiers in the EU during the current financial year and reduce customer concentration by entering newer geographies and adding niche products. The company said it plans a new production block at Lote and a nasal line, supported by 12,551 square metres of adjacent land acquired for future expansion. Management also said the Ambernath API R&D facility is fully commissioned with 16 scientists and that a GLP-1 portfolio is being developed and supplied for a leading Indian generics company.
Results were filed after market hours
The standalone results were filed on 13 August 2026 at 18:59 IST, after the market closed. The filing therefore did not have an immediate in-session market reaction.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹190 cr |
| Other income | ₹3 cr |
| Expenses | ₹142 cr |
| Operating profit | ₹47 cr |
| Operating margin (%) | 25.01% |
| Interest | ₹0 cr |
| Depreciation | ₹9 cr |
| Profit before tax | ₹41 cr |
| Tax | ₹17 cr |
| Net profit | ₹24 cr |
| EPS (₹) | ₹2.99 |
Operating margin of 25.01% compares with a Healthcare sector median of 22.95% across 69 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company plans to file six dossiers in the EU during the current financial year.
- The company plans to reduce customer concentration by penetrating newer geographies and adding niche products.
Expansion
- The company plans a new production block at Lote to expand capacity.
- The company plans a new nasal line to strengthen finished dosage capabilities.
- The company acquired 12,551 square metres adjacent to its existing facility for future growth and expansion.
New products
- A key cardiovascular product was launched in Q3FY26 and began contributing revenue in Q4FY26.
- A liquid anesthetic product has been commercialised, with steady monthly supplies underway.
New initiatives
- The Ambernath API R&D facility is fully commissioned with a team of 16 scientists.
- The company is developing and supplying a GLP-1 portfolio for a leading Indian generics company.
- The company has filed two patents this year as part of its focus on innovation and IP creation.
- The company developed and patented a novel Semaglutide tablet formulation.
- The company is evaluating exclusive manufacturing rights in liquid inhalation products.
What to watch
- Progress toward management's plan to file six EU dossiers during the current financial year.
- Whether operating margin holds above the 25.01% reported in Q1FY27 and the 22.95% healthcare peer median.
- Updates on the 12,551-square-metre expansion site, the Lote production block and the planned nasal line.